Product Name:2,6-Dichloro-5-fluoronicotinamide

IUPAC Name:2,6-dichloro-5-fluoropyridine-3-carboxamide

CAS:113237-20-0
Molecular Formula:C6H3Cl2FN2O
Purity:98%
Catalog Number:CM178393
Molecular Weight:209

Packing Unit Available Stock Price($) Quantity
CM178393-500g in stock Ǖƙſ
CM178393-1000g in stock ȦƋƱ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:113237-20-0
Molecular Formula:C6H3Cl2FN2O
Melting Point:-
Smiles Code:O=C(N)C1=C(Cl)N=C(Cl)C(F)=C1
Density:
Catalog Number:CM178393
Molecular Weight:209
Boiling Point:
MDL No:MFCD01571365
Storage:Store at room temperature

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Sotorasib
Dec. 26, 2023, Amgen announced that the U.S. FDA has completed its review of the company's supplemental New Drug Application seeking full approval of LUMAKRAS (sotorasib).
LUMAKRAS (sotorasib) is an oral, first-in-class therapy indicawithted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) following at least one previous systemic therapy.
Sotorasib is the first approved targeted therapy for patients with tumors with any KRAS mutation, which accounts for approximately 25% of mutations in NSCLC. The U.S. FDA granted the application for sotorasib orphan drug, fast track, priority review, and breakthrough therapy designations.

Related Products